Vol 4: Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.Report as inadecuate



 Vol 4: Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.


Vol 4: Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 4: Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.
This article is from Frontiers in Oncology, volume 4.AbstractLung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all patients diagnosed with lung cancer remains between 15 and 20%. Newer therapeutic strategies rely on specific molec

Author: Korpanty, Grzegorz J.; Graham, Donna M.; Vincent, Mark D.; Leighl, Natasha B.

Source: https://archive.org/







Related documents